-
EVALUATION OF SAFETY, EFFICACY, AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH ABNORMAL UTERINE BLEEDING TREATED WITH LEVONORGESTREL INTRAUTERINE SYSTEM
Feb 25, 2026, 14:41 PM -
BUDGET IMPACT OF INTRODUCING PIRTOBRUTINIB AFTER COVALENT BRUTON TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA IN THE US
Feb 25, 2026, 14:41 PM -
REAL-WORLD USE OF BIOLOGICS IN CROHN’S DISEASE: ALIGNMENT WITH HEALTH PLAN COVERAGE REQUIREMENTS
Feb 25, 2026, 14:41 PM -
USING EXTENDED COX MODELS WITH TIME-VARYING COVARIATES TO EXAMINE EFFECT OF VARIABLE OPIOID EXPOSURE IN CANCER RECURRENCE IN DISEASE-FREE BREAST CANCER SURVIVORS
Feb 25, 2026, 14:41 PM -
ECONOMIC EVALUATION OF TARGETED PERINATAL DEPRESSION SCREENING FOR HIGH-RISK WOMEN IN CHINA
Feb 25, 2026, 14:41 PM -
ECONOMIC IMPACT OF CARDIOVASCULAR BENEFIT OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH OVERWEIGHT OR OBESITY IN CHINA
Feb 25, 2026, 14:41 PM -
PREVALENCE, RISK FACTORS, AND SAFETY IMPLICATIONS OF POTENTIALLY INAPPROPRIATE MEDICATION USE AMONG OLDER ADULTS WITH DEMENTIA: A SYSTEMATIC REVIEW
Feb 25, 2026, 14:41 PM -
INSIGHTS INTO RANGE OF MOTION (ROM) AND PHYSICAL FUNCTION (PF) CHANGES EXPERIENCED BY PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) IN THE MANEUVER PHASE 3 TRIAL: RESULTS FROM EXIT INTERVIEWS
Feb 25, 2026, 14:41 PM -
DRUG SHORTAGES FINAL RULE RETROSPECTIVE ANALYSIS
Feb 25, 2026, 14:41 PM -
COMPARATIVEEFFECTIVENESS OF ANTIBIOTICS PLUS SUHUANG ZHIKE CAPSULES VERSUS ANTIBIOTICS ALONE FOR COUGH USING REAL-WORLD DATA
Feb 25, 2026, 14:41 PM -
ONE BIG BEAUTIFUL ACT (OBBA) MEDICAID FUNDING CHANGES IMPACT ON MEDICAID VOLUMES IN CLAIMS DATA; A STUDY OF IMPACT FROM REENROLLMENT REQUIREMENTS OF 2024
Feb 25, 2026, 14:41 PM -
COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS IN ADULTS WITH SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA: A U.S. PAYER PERSPECTIVE MARKOV MODEL
Feb 25, 2026, 14:41 PM -
EXPANDING ACCESS TO LONG-ACTING REVERSIBLE CONTRACEPTIVES: A STATE-LEVEL BUDGET IMPACT MODEL OF SOUTH CAROLINA
Feb 25, 2026, 14:41 PM -
REAL-WORLD (RW) DISEASE PROGRESSION AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE UNITED STATES (US)
Feb 25, 2026, 14:41 PM -
SOCIETAL IMPACT ASSESSMENT OF OFATUMUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A 5-PILLAR ANALYSIS FROM A SOCIETAL PERSPECTIVE
Feb 25, 2026, 14:41 PM -
THE FEASIBILITY OF MEASURING BTKI MEDICATION ADHERENCE IN THE TREATMENT OF CLL/SLL USING AN ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) PLATFORM
Feb 25, 2026, 14:41 PM -
DIVERSITY IN CLINICAL TRIALS: A REVIEW OF DRUGS APPROVED BY THE FDA IN 2024
Feb 25, 2026, 14:41 PM -
UNDERSTANDING DISEASE COMPLEXITY IN GRAVES’ DISEASE: A POPULATION-BASED NETWORK ANALYSIS OF COMORBIDITIES
Feb 25, 2026, 14:41 PM -
ROBOTIC-ASSISTED PYELOPLASTY USING THE DA VINCI SURGICAL SYSTEMS COMPARED TO LAPAROSCOPIC OR OPEN APPROACH: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:41 PM -
COMPARING HTA DECISIONS, PRICING NEGOTIATIONS, AND REIMBURSEMENT OF INFLIXIMAB BIOLOGIC ORIGINATOR AND BIOSIMILARS IN CANADA
Feb 25, 2026, 14:41 PM
